New combo therapy aims to shrink eye tumors before radiation
NCT ID NCT05893654
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tests whether injecting the chemotherapy drug melphalan directly into the eye's blood vessels can shrink large uveal melanomas (eye cancers) enough to then treat them with radiation. Ten adults with tumors at least 8 mm thick will receive the chemo injection followed by a radioactive plaque placed on the eye. Researchers will monitor safety (retinal function) and tumor shrinkage over 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Melphalan (chemotherapy drug)
What this could lead to
If successful, this approach could shrink large eye tumors enough to allow effective radiation therapy, potentially saving more eyes from removal.
What could go wrong
This is a very early, small trial (10 people) focused on safety. The chemo may cause retinal toxicity, and it is unknown if the combination will work better than standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto - USP
Ribeirão Preto, São Paulo, 14040-906, Brazil